Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Description

use of lanadelumab in patients with acquired angioedema

Conditions

Angioedema

Talk to us

Study Overview

On this page

Study Details

Study overview

use of lanadelumab in patients with acquired angioedema

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Condition
Angioedema
Intervention / Treatment

-

Contacts and Locations

Cincinnati

Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, United States, 45236

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance)
  • * historical attack rate of \>= on attack per month prior to starting tranexamic acid (TAA)
  • * History of anaphylaxis or hypersensitivity to biologics
  • * History of major systemic disease not well controlled in opinion of the PI
  • * Women who are pregnant or breast feeding
  • * Concurrent participation in other clinical trials
  • * HAE Type 1 or 2 and normal complement HAE

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bernstein Clinical Research Center,

Jonathan Bernstein, MD, PRINCIPAL_INVESTIGATOR, 5139314181

Study Record Dates

2027-12-01